The MS Trust is very disappointed that Nice is unable to recommend siponimod (Mayzent) as an NHS treatment for active secondary progressive MS.
However, Nice has concluded that they are unable to recommend siponimod as a cost-effective treatment for the NHS for England and Wales without more detailed evidence and analysis of the data.
We are hugely disappointed by this initial decision. Time and time again, we hear from people with secondary progressive MS struggling at home, feeling like they have been forgotten. Just earlier this month, a new report has highlighted the significant gaps in support and services for people with SPMS. Not everybody will be eligible for siponimod, but we hope that the availability of a new treatment will lead to a renewed focus on the needs of all people with SPMS.
- David Martin, Chief Executive, MS Trust
The MS Trust is reviewing Nice’s decision and we will continue to make the strongest possible case for NHS approval.
We encourage people to add their own comments on this initial decision; you can do so via the Nice website by 5pm on Thursday 23 July 2020.
Nice will meet again to review this decision in the light of comments received and further evidence from the manufacturer; the date for this meeting has not been confirmed.
The Scottish Medicines Consortium has also scheduled an appraisal of siponimod but this is currently on hold. In Northern Ireland, the Department of Health reviews Nice guidance.
Siponimod is taken as a tablet, once a day.
In clinical trials for secondary progressive MS, siponimod reduced the risk of disability getting worse by 26% compared to placebo. Further analysis indicated a 37% reduction in the risk of worsening disability for those with active SPMS, defined as those who had relapsed in the two years prior to starting the trial or showed MRI evidence of MS activity.
In clinical trials, low white blood cell count, increased liver enzyme levels, slower heart rate when starting treatment, macular oedema (swelling in the back of the eye affecting vision), high blood pressure, shingles, and convulsions occurred more frequently with siponimod than with placebo.
New study provides strong evidence for role of Epstein Barr virus as a trigger for multiple sclerosis
14 Jan 2022 - 00:00
New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.
The PANORAMIC trial for Covid-19 treatment
23 Dec 2021 - 00:00
If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.
Ponvory (ponesimod) approved for relapsing remitting MS in England and Wales
23 Dec 2021 - 00:00
The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.